Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  New England Journal of Medicine

• Publication date

  1992-05-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM199205283262204PMID 1349424
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Excitatory amino acids in amyotrophic lateral sclerosis: An update

  1991cited by this paper
• The quantitative autoradiographic distribution of [3H]MK-801 binding sites in the normal human spinal cord.

  1991cited by this paper
• Pharmacologically distinct sodium-dependent L-[3H]glutamate transport processes in rat brain.

  1991cited by this paper
• Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS.

  1991cited by this paper
• Neurotoxic effects of excitatory amino acids in the mouse spinal cord: quisqualate and kainate but not N-methyl-D-aspartate induce permanent neural damage.

  1990cited by this paper
• Abusive stimulation of excitatory amino acid receptors: a strategy to limit neurotoxicity

  1990cited by this paper
• Activation of Glutamate Dehydrogenase by Leucine and Its Nonmetabolizable Analogue in Rat Brain Synaptosomes

  1990cited by this paper
• Morphometric studies in dominant olivopontocerebellar atrophy. Comparison of cell losses with amino acid decreases.

  1990cited by this paper
• The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death.

  1990cited by this paper
• The release and uptake of excitatory amino acids.

  1990cited by this paper
• What excitotoxin kills striatal neurons in Huntington's disease? Clues from neurochemical studies

  1990cited by this paper
• Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis

  1990cited by this paper
• NMDA receptors mediate poly- and monosynaptic potentials in motoneurons of rat embryos

  1990cited by this paper
• Neurotoxicity of beta-N-methylamino-L-alanine (BMAA) and beta-N-oxalylamino-L-alanine (BOAA) on cultured cortical neurons.

  1989cited by this paper
• Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis

  1989cited by this paper
• The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis

  1988cited by this paper
• Glutamate neurotoxicity and diseases of the nervous system.

  1988cited by this paper
• Quinoxalinediones selectively block quisqualate and kainate receptors and synaptic events in rat neocortex and hippocampus and frog spinal cord in vitro

  1988cited by this paper
• Regional changes in [3H]D-aspartate and [3H]TCP binding sites in Alzheimer's disease brains.

  1988cited by this paper
• Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis.

  1988cited by this paper
• NMDA receptor losses in putamen from patients with Huntington's disease.

  1988cited by this paper
• Brain glutamate deficiency in amyotrophic lateral sclerosis

  1987cited by this paper
• Uptake of gamma-aminobutyric acid and glycine by synaptosomes from postmortem human brain.

  1986cited by this paper
• Uptake of γ‐Aminobutyric Acid and Glycine by Synaptosomes from Postmortem Human Brain

  1986cited by this paper
• Analysis of aspartate and glutamate in human cerebrospinal fluid by high-performance liquid chromatography with automated precolumn derivatization.

  1986cited by this paper
• Comparative toxicities of alpha- and beta-N-oxalyl-L-alpha, beta-diaminopropionic acids to rat spinal cord.

  1985cited by this paper
• Glial and neuronal glutamate transport following glutamine synthetase inhibition.

  1985cited by this paper
• Neurotoxicity of L‐Glutamate and DL‐Threo‐3‐Hydroxyaspartate in the Rat Striatum

  1985cited by this paper
• Comparative toxicities of α- and β-N-oxalyl-l-α,β-diaminopropionic acids to rat spinal cord

  1985cited by this paper
• Manual of Pharmacologic Calculations: With Computer Programs

  1984cited by this paper
• Elevated levels of amino acids in the CSF of motor neuron disease patients.

  1984cited by this paper
• Glutamate: A Neurotransmitter in Mammalian Brain

  1984cited by this paper
• Post-mortem high affinity glutamate uptake in human brain.

  1982cited by this paper
• Pathology of amyotrophic lateral sclerosis.

  1982cited by this paper
• Glutamate dehydrogenase deficiency in three patients with spinocerebellar syndrome

  1980cited by this paper
• Kinetics of Cerebral Uptake Processes In Vitro of L‐Glutamine, Branched‐Chain L‐Amino Acids, and L‐Phenylalanine: Effects of Ouabain

  1980cited by this paper
• A comparison of sodium-dependent glutamate binding with high-affinity glutamate uptake in rat striatum.

  1980cited by this paper
• Stereospecificity of the inhibition of l‐glutamate and l‐aspartate high affinity uptake in rat brain slices by threo‐3‐hydroxyaspartate

  1977cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Targeting the Gut Microbiota: Mechanistic Investigation of Polyphenol Modulation of the Gut–Brain Axis in Alzheimer’s Disease

  2026cites this paper
• Focus on the excitatory and inhibitory neurotransmission imbalance in amyotrophic lateral sclerosis: a harmful disease player or a potential therapeutic opportunity?

  2026cites this paper
• The NMDAR/TRPM4 death complex is a major promoter of disease progression in the 5xFAD mouse model of Alzheimer’s disease

  2025cites this paper
• A hydrogen bond-triggered excimer probe for dynamic monitoring of aspartic acid and glutamic acid.

  2025cites this paper
• Network Dysfunction Precedes Neurodegeneration in a dox-Regulatable TDP-43 Mouse Model of ALS-FTD

  2025cites this paper
• Increased ATP production and P‐glycoprotein activity underlie the marked changes in blood–brain barrier transport of drugs in a mouse model of amyotrophic lateral sclerosis

  2025cites this paper
• Sensory Dysfunction in ALS and Other Motor Neuron Diseases: Clinical Relevance, Histopathology, Neurophysiology, and Insights from Neuroimaging

  2025cites this paper
• Muscle Matters: Transforming Amyotrophic Lateral Sclerosis Diagnostics with Next-Gen Biosensors and Smart Detection.

  2025cites this paper
• Sonographic Evaluation of Peripheral Nerves and Cervical Nerve Roots in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis

  2025cites this paper
• Longitudinal assessment of cortical motor function in amyotrophic lateral sclerosis

  2025cites this paper
• Brain distribution study of [14C]-Riluzole following intranasal administration in mice.

  2025cites this paper
• Conformational free energy landscape of a glutamate transporter and microscopic details of its transport mechanism

  2025cites this paper
• The many roads to dementia: a systems view of Alzheimer's disease

  2025cites this paper
• An unrecognized mechanism of self-protection in degenerating neurons mediated by astrocytic YAP through Wnts/β-catenin/EAAT2 signaling in C9orf72-poly-GA mice

  2025cites this paper
• Xenon in ALS Treatment: What Are We Waiting for?

  2025cites this paper
• Cell and gene therapy for amyotrophic lateral sclerosis.

  2024cites this paper
• Advancements and challenges in amyotrophic lateral sclerosis

  2024influential citation
• Hybrid virtual screening and molecular dynamics approach for identification of allosteric modulator of EAAT2

  2024cites this paper
• Homozygous ALS-linked mutations in TARDBP/TDP-43 lead to hypoactivity and synaptic abnormalities in human iPSC-derived motor neurons

  2024cites this paper
• Towards an integrated approach for understanding glia in Amyotrophic Lateral Sclerosis

  2024cites this paper
• Dietary NMN supplementation enhances motor and NMJ function in ALS.

  2024cites this paper
• Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis.

  2024cites this paper
• TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS

  2024cites this paper
• Effects of novel beta-lactam, MC-100093, and ceftriaxone on astrocytic glutamate transporters and neuroinflammatory factors in nucleus accumbens of C57BL/6 mice exposed to escalated doses of morphine

  2024cites this paper
• TwinF interface inhibitor FP802 prevents retinal ganglion cell loss in a mouse model of amyotrophic lateral sclerosis

  2024cites this paper
• Nuclear Localization of Human SOD1 in Motor Neurons in Mouse Model and Patient Amyotrophic Lateral Sclerosis: Possible Links to Cholinergic Phenotype, NADPH Oxidase, Oxidative Stress, and DNA Damage

  2024cites this paper
• Neuronal DSCAM regulates the peri-synaptic localization of GLAST in Bergmann glia for functional synapse formation

  2024cites this paper
• Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer’s disease

  2024cites this paper
• Perspective role of Substance P in Amyotrophic Lateral Sclerosis: from neuronal vulnerability to neuroprotection.

  2024cites this paper
• Therapeutic targeting of the oxidative stress generated by pathological molecular pathways in the neurodegenerative diseases, ALS and Huntington's.

  2024cites this paper
• A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis

  2024cites this paper
• The glutamatergic system in Alzheimer’s disease: a systematic review with meta-analysis

  2024cites this paper
• How do we get from hyperexcitability to excitotoxicity in amyotrophic lateral sclerosis?

  2024cites this paper
• Inflammatory cytokines disrupt astrocyte exosomal HepaCAM-mediated protection against neuronal excitotoxicity in the SOD1G93A ALS model

  2024cites this paper
• Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis

  2024cites this paper
• Riluzole treatment modulates KCC2 and EAAT-2 receptor expression and Ca2+ accumulation following ventral root avulsion injury.

  2023cites this paper
• Sink or swim: Does a worm paralysis phenotype hold clues to neurodegenerative disease?

  2023influential citation
• Glutamate Neurotoxicity in ALS and Epilepsy

  2023cites this paper
• Insights on the Multifaceted Roles of Wild-Type and Mutated Superoxide Dismutase 1 in Amyotrophic Lateral Sclerosis Pathogenesis

  2023cites this paper
• Targeting mitochondrial Ca2+ uptake for the treatment of amyotrophic lateral sclerosis

  2023cites this paper
• Effects of Beta Lactams on Behavioral Outcomes of Substance Use Disorders: A Meta-Analysis of Preclinical Studies.

  2023cites this paper
• AMPKα1 Deficiency in Astrocytes from a Rat Model of ALS Is Associated with an Altered Metabolic Resilience

  2023cites this paper
• A Review on Neuroinflammatory Pathway Mediating Through Ang-II/AT1 Receptors and a Novel Approach for the Treatment of Cerebral Ischemia in Combination with ARB’s and Ceftriaxone

  2023cites this paper
• Roles of Aging, Circular RNAs, and RNA Editing in the Pathogenesis of Amyotrophic Lateral Sclerosis: Potential Biomarkers and Therapeutic Targets

  2023cites this paper
• Novel approaches to motoneuron disease/ALS treatment using non-invasive brain and spinal stimulation: IFCN handbook chapter.

  2023cites this paper
• SOMAscan Proteomics Identifies Novel Plasma Proteins in Amyotrophic Lateral Sclerosis Patients

  2023cites this paper
• The role of astrocytes with genetic mutations linked to amyotrophic lateral sclerosis

  2023cites this paper
• Homozygous ALS-linked mutations in TARDBP/TDP-43 lead to progressive synaptic dysfunction in human iPSC-derived motor neurons

  2023cites this paper
• The Fault in Our Astrocytes - cause or casualties of proteinopathies of ALS/FTD and other neurodegenerative diseases?

  2023cites this paper
• Repetitive spreading depolarization induces gene expression changes related to synaptic plasticity and neuroprotective pathways

  2023cites this paper
• Extracellular Vesicles as Potential Biomarkers in Amyotrophic Lateral Sclerosis

  2023cites this paper
• A Medicinal Chemistry Perspective on Excitatory Amino Acid Transporter 2 Dysfunction in Neurodegenerative Diseases

  2023cites this paper
• Outils thérapeutiques dans la sclérose latérale amyotrophique : enfin du nouveau !

  2023cites this paper
• Neurotransmitter Systems in the Etiology of Major Neurological Disorders: Emerging Insights and Therapeutic Implications.

  2023cites this paper
• Riluzole, a neuroprotective agent, preserves erectile function following bilateral cavernous nerve injury in male rats

  2023cites this paper
• Brain-derived neurotrophic factor/tropomyosin receptor kinase B signaling in spinal muscular atrophy and amyotrophic lateral sclerosis.

  2023cites this paper
• The biochemical basis of neurodegenerative disease: The role of immunoexcitoxicity and ways to possibly attenuate it

  2023cites this paper
• La sclérose latérale amyotrophique : une maladie neurodégénérative emblématique

  2023cites this paper
• Therapeutic targeting of ALS pathways: Refocusing an incomplete picture

  2023cites this paper
• Inhibitory interneurons show early dysfunction in a SOD1 mouse model of amyotrophic lateral sclerosis

  2022cites this paper
• Biomarkers and molecular mechanisms of Amyotrophic Lateral Sclerosis

  2022cites this paper
• Poly(ADP-ribose) promotes toxicity of C9ORF72 arginine-rich dipeptide repeat proteins

  2022cites this paper
• Breakdown of the central synapses in C9orf72-linked ALS/FTD

  2022cites this paper
• Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.

  2022cites this paper
• Array tomography: 15 years of synaptic analysis

  2022cites this paper
• WNT/β-catenin Pathway: a Possible Link Between Hypertension and Alzheimer’s Disease

  2022cites this paper
• Astrocyte energy and neurotransmitter metabolism in Alzheimer's disease: integration of the glutamate/GABA-glutamine cycle.

  2022cites this paper
• Purinergic P2X7 Receptor: A Therapeutic Target in Amyotrophic Lateral Sclerosis.

  2022cites this paper
• Ceftriaxone as a Novel Therapeutic Agent for Hyperglutamatergic States: Bridging the Gap Between Preclinical Results and Clinical Translation

  2022cites this paper
• Interaction of Mitochondrial Calcium and ROS in Neurodegeneration

  2022cites this paper
• Pathogenic Extracellular Vesicle (EV) Signaling in Amyotrophic Lateral Sclerosis (ALS)

  2022cites this paper
• Cortical and subcortical changes in resting-state neuronal activity and connectivity in early symptomatic ALS and advanced frontotemporal dementia

  2022cites this paper
• EAAT2 as a therapeutic research target in Alzheimer's disease: A systematic review

  2022cites this paper
• Induction of Survival of Motor Neuron (SMN) Protein Deficiency in Spinal Astrocytes by Small Interfering RNA as an In Vitro Model of Spinal Muscular Atrophy

  2022cites this paper
• Is L-Glutamate Toxic to Neurons and Thereby Contributes to Neuronal Loss and Neurodegeneration? A Systematic Review

  2022cites this paper
• Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders

  2022cites this paper
• Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases.

  2022cites this paper
• Pharmacological evidence for the concept of spare glutamate transporters.

  2021cites this paper
• A beneficial role for elevated extracellular glutamate in Amyotrophic Lateral Sclerosis and cerebral ischemia

  2021cites this paper
• Neurotransmitter Release of Reprogrammed Cells Using Electrochemical Detection Methods.

  2021cites this paper
• Microbial Infections Are a Risk Factor for Neurodegenerative Diseases

  2021cites this paper
• Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration.

  2021cites this paper
• Comparing astrocytic gap junction of genetic absence epileptic rats with control rats: an experimental study

  2021cites this paper
• Glutamate Transporters: Critical components of glutamatergic transmission.

  2021cites this paper
• Observing spontaneous, accelerated substrate binding in molecular dynamics simulations of glutamate transporters

  2021cites this paper
• Trimetazidine Modulates Mitochondrial Redox Status and Disrupted Glutamate Homeostasis in a Rat Model of Epilepsy

  2021cites this paper
• Blocking glutamate mGlu5 receptors with the negative allosteric modulator CTEP improves disease course in SOD1G93A mouse model of amyotrophic lateral sclerosis

  2021cites this paper
• Destination Amyotrophic Lateral Sclerosis

  2021cites this paper
• MR spectroscopy and imaging-derived measurements in the supplementary motor area for biomarkers of amyotrophic lateral sclerosis

  2021cites this paper
• Glutamic Acid Decarboxylase Concentration Changes in Response to Stress and Altered Availability of Glutamic Acid in Rabbit (Oryctolagus cuniculus) Brain Limbic Structures

  2021cites this paper
• Brain Stimulation as a Therapeutic Tool in Amyotrophic Lateral Sclerosis: Current Status and Interaction With Mechanisms of Altered Cortical Excitability

  2021cites this paper
• Multi-phaseted problems of TDP-43 in selective neuronal vulnerability in ALS

  2021cites this paper
• Astrocyte-immune cell interactions in physiology and pathology.

  2021cites this paper
• Circulating cell-free DNA as potential diagnostic tools for amyotrophic lateral sclerosis.

  2021cites this paper
• CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target?

  2021cites this paper
• Regulation of neuronal bioenergetics as a therapeutic strategy in neurodegenerative diseases

  2021cites this paper
• Expression and cell type-specific localization of inflammasome sensors in the spinal cord of SOD1(G93A) mice and sALS patients.

  2021cites this paper
• Critical amino acids in the TM2 of EAAT2 are essential for membrane‐bound localization, substrate binding, transporter function and anion currents

  2021cites this paper
• Differential Effects of Human P301L Tau Expression in Young versus Aged Mice

  2021cites this paper
• RNA Editing: A New Therapeutic Target in Amyotrophic Lateral Sclerosis and Other Neurological Diseases

  2021cites this paper